研究建立胃癌靶向治疗机制的模型，探讨西妥昔单抗治疗的反应和耐药因素。

建立西妥昔单抗治疗胃癌细胞系模型。捕获两种不同突变模式的胃癌细胞系中的表皮生长因子受体（EGFR）、细胞外调节蛋白激酶（ERK）和蛋白激酶B（AKT）信号通路。采用MatLab工具箱及ImageJ软件进行统计学数据及图像处理，使用时间和剂量反应测量的综合选择来训练模型，并提供参数和预测不确定性的评估。

胃癌细胞系模型有助于识别细胞系之间的因果差异。提供了对不同扰动的响应预测，例如打击和淘汰实验。在其他结果中，该模型预测了酪氨酸激酶受体（MET）突变对西妥昔单抗敏感性的影响。

这些预测能力使该模型成为评估胃癌细胞系信号以及可能开发和发现预测生物标记物的基础。

The aim of this study was to establish a mechanism model of targeted therapy for gastric cancer in order to study the response and resistance factors of cetuximab therapy.

In this study，cetuximab treatment of gastric cancer cell line model was established. The model captures the epidermal growth factor receptor（EGFR），extracellular regulatory protein kinase（ERK），and protein kinase B（AKT）signaling pathways in two gastric cancer cell lines with different mutation patterns. The MatLab toolbox and ImageJ software were used for statistical data and image processing，and a comprehensive selection of time and dose response measurements was used to train the model and provide an assessment of parameters and prediction uncertainties.

The model presented in this paper helps to identify causal differences between cell lines. The study shows that the model provides predictions of responses to different perturbations，such as strike and elimination experiments. Among other results，the model predicted the effect of tyrosine kinase receptor（MET）mutations on cetuximab sensitivity.

These predictive capabilities make the model a basis for evaluating gastric cancer cell line signaling and possibly developing and discovering predictive biomarkers.